Cargando…
Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study
Autores principales: | Medina-Pestana, José, Teixeira, Cinthia Montenegro, Cristelli, Marina Pontello, Amiratti, Adriano Luiz, Manfredi, Silvia Regina, Tedesco-Silva, Helio, Covas, Dimas Tadeu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690086/ https://www.ncbi.nlm.nih.gov/pubmed/34950472 http://dx.doi.org/10.1093/ckj/sfab146 |
Ejemplares similares
-
Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study
por: Medina-Pestana, José, et al.
Publicado: (2021) -
Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021) -
Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022) -
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022) -
Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023)